martes, 5 de septiembre de 2017

Osteosarcoma and MFH of Bone Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Osteosarcoma and MFH of Bone Treatment (PDQ®)—Health Professional Version - National Cancer Institute

National Cancer Institute

Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (08/31/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for recurrent osteosarcoma and MFH of bone.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: August 31, 2017

No hay comentarios:

Publicar un comentario